Literature DB >> 16287338

Should we screen for Alzheimer's disease? A review of the evidence for and against screening Alzheimer's disease in primary care practice.

Paul R Solomon1, Cynthia A Murphy.   

Abstract

Fewer than one-half of all Alzheimer's disease (AD) patients are currently diagnosed; approximately 25% are treated with antidementia compounds. Screening has been proposed to help combat underdiagnosis of AD. An emerging consensus suggest that the three keys to the successful treatment of Alzheimer's disease are early detection, use of currently approved medications to provide symptomatic treatment, and development of medications to slow and eventually halt disease progression. If early detection of Alzheimer's disease is the first step, screening would seem to be an important strategy. We review the arguments for and against screening and suggest several strategies and instruments that may be helpful in the context of screening for Alzheimer's disease in primary care practice.

Entities:  

Mesh:

Year:  2005        PMID: 16287338

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  25 in total

1.  Age patterns of incidence of geriatric disease in the U.S. elderly population: Medicare-based analysis.

Authors:  Igor Akushevich; Julia Kravchenko; Svetlana Ukraintseva; Konstantin Arbeev; Anatoliy I Yashin
Journal:  J Am Geriatr Soc       Date:  2012-01-27       Impact factor: 5.562

Review 2.  Health care experiences of people with dementia and their caregivers: a meta-ethnographic analysis of qualitative studies.

Authors:  Jeanette C Prorok; Salinda Horgan; Dallas P Seitz
Journal:  CMAJ       Date:  2013-09-03       Impact factor: 8.262

Review 3.  A review of screening tests for cognitive impairment.

Authors:  Breda Cullen; Brian O'Neill; Jonathan J Evans; Robert F Coen; Brian A Lawlor
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

4.  The measurement of everyday cognition: development and validation of a short form of the Everyday Cognition scales.

Authors:  Sarah Tomaszewski Farias; Dan Mungas; Danielle J Harvey; Amanda Simmons; Bruce R Reed; Charles Decarli
Journal:  Alzheimers Dement       Date:  2011-11       Impact factor: 21.566

5.  Rapid In-Person Cognitive Screening in the Preoperative Setting: Test Considerations and Recommendations from the Society for Perioperative Assessment and Quality Improvement (SPAQI).

Authors:  Franchesca Arias; Margaret Wiggins; Richard D Urman; Rebecca Armstrong; Kurt Pfeifer; Angela M Bader; David J Libon; Anita Chopra; Catherine C Price
Journal:  Perioper Care Oper Room Manag       Date:  2020-01-25

6.  Development of a rapid screening instrument for mild cognitive impairment and undiagnosed dementia.

Authors:  N Kyle Steenland; Courtney M Auman; Purvi M Patel; Scott M Bartell; Felicia C Goldstein; Allan I Levey; James J Lah
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

Review 7.  Brief Cognitive Tests in the Case of Dementia and Alzheimer's Disease Early Diagnosis.

Authors:  Maria Sagiadinou; Antonia Plerou
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 8.  Improving dementia care: the role of screening and detection of cognitive impairment.

Authors:  Soo Borson; Lori Frank; Peter J Bayley; Malaz Boustani; Marge Dean; Pei-Jung Lin; J Riley McCarten; John C Morris; David P Salmon; Frederick A Schmitt; Richard G Stefanacci; Marta S Mendiondo; Susan Peschin; Eric J Hall; Howard Fillit; J Wesson Ashford
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

9.  The source of cognitive complaints predicts diagnostic conversion differentially among nondemented older adults.

Authors:  Katherine A Gifford; Dandan Liu; Zengqi Lu; Yorghos Tripodis; Nicole G Cantwell; Joseph Palmisano; Neil Kowall; Angela L Jefferson
Journal:  Alzheimers Dement       Date:  2013-07-16       Impact factor: 21.566

10.  Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study.

Authors:  Pedro Gil; José Luis Dobato Ayuso; José Manuel Marey; Manuel Antón; Carlos Guzmán Quilo
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.